title: Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia.
abstract: Objective : This study is to determine the curative effect of β-elemene emulsion on chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML). Methods : In the β-elemene emulsion plus HAA chemotherapy (harringtonine, aclacinomycin, Ara-c group) group, 120 cases received β-elemene emulsion (400 mg) plus the HAA treatment. A 14-day treatment was a course of treatment, followed by an 8-14 day pause, and then the next course of treatment. The HAA treatment included Ara-C, 100 mg/m2, once every 12 h from day 1 to day 7; aclacinomycin, 20 mg/m2, from day 1 to day 7; and homoharringtonine, 4 mg/m2, from day 1 to day 7. The patients in the control HAA group received HAA treatment only. For both groups, effective antibiotics were given to patients when it was necessary. Results : The total effective rate in the β-elemene emulsion plus HAA group was 80.8%. But the total effective rate in the HAA only group was 52.9%. These results suggest that the β-elemene emulsion plus HAA treatment has a much better curative effect in comparison with the HAA only treatment (P < 0.05). Furthermore, β-elemene emulsion has slightly adverse response, without causing blood and bone marrow depression. Conclusion : β-elemene emulsion has a curative effect in treatment of refractory/relapsed AML in combination with harringtonine, aclacinomycin, and Ara-c.
authors: Cuiping Zheng, Department of Blood Chemotherapy, The Central Hospital, Wenzhou, 325000, P. R. China.
authors: Cuiping
authors: C
authors: Zheng
authors: Xiaoping Cai, Department of Blood Chemotherapy, The Central Hospital, Wenzhou, 325000, P. R. China.
authors: Xiaoping
authors: X
authors: Cai
authors: Shenghao Wu, Department of Blood Chemotherapy, The Central Hospital, Wenzhou, 325000, P. R. China.
authors: Shenghao
authors: S
authors: Wu
authors: Zhen Liu, Department of Blood Chemotherapy, The Central Hospital, Wenzhou, 325000, P. R. China.
authors: Zhen
authors: Z
authors: Liu
authors: Yuejian Shi, Department of Blood Chemotherapy, The Central Hospital, Wenzhou, 325000, P. R. China.
authors: Yuejian
authors: Y
authors: Shi
authors: Wenjin Zhou, Department of Blood Chemotherapy, The Central Hospital, Wenzhou, 325000, P. R. China.
authors: Wenjin
authors: W
authors: Zhou
keywords: chemotherapy; leukemia; refractory/relapsed AML; β-elemene